Patient-centered adverse event reporting in clinical trials: A novel approach using ECOG-ACRIN E2211.

658 Background: The Common Terminology Criteria for Adverse Events (CTCAE) classifies adverse events (AEs) in clinical trials but traditionally limits the analysis to a single occurrence per patient and grade 3-4 AEs, overlooking frequent and lower grade AEs. We propose a new approach of AE reporting that captures both the safety profile and patient experience. Methods: We analyzed related AEs collected in the ECOG-ACRIN E2211 [Phase II capecitabine + temozolomide (Arm A) vs. temozolomide (Arm B) in advanced pancreatic neuroendocrine neoplasms] by CTCAE v4.0 and limited to hematologic and gastrointestinal (GI) categories for this exploratory analysis. We calculated AE burden, defined as the average occurrence of AE per patient experiencing the AE, measured by total occurrence of AEs, and divided by number of patients who developed the AE. We then compared burden of grade 3-4 AEs vs. grades 1-4 AEs. Sex differences were evaluated using t-tests. Results: For hematologic AEs, 72 patients reported 426 occurrences across grades 1-4 and 24 patients reported 39 occurrences for grades 3-4, resulting in AE burdens of 5.9 (grades 1-4) versus 1.6 (grades 3-4). For GI AEs, 108 patients reported 997 grade 1-4 events, and 13 patients reported 22 grade 3-4 events, resulting in AE burdens of 9.23 versus 1.69, respectively. Sex differences in AE burden are tabulated below (Table). For example, in Arm B, anemia burden was 4.8 (males) vs 2.7 (females) [p=0.068] for grades 1-4 and 0 (males) vs 1 (females) for grades 3 and 4. Conclusions: This AE reporting approach, accounting for the burden across grade 1-4, offers a different and more patient-centered assessment of AEs in clinical trials and may help better identify sex-based differences. Burden of AEs by treatment arm and sex distribution. Burden of Related AEs Categories of AEs Arm A (N=65) Arm B (N=68) Grade 1-Grade 4 Grade 3-Grade 4 Grade 1-Grade 4 Grade 3-Grade 4 Male Female p-value Male Female p-value Male Female p-value Male Female p-value Hematologic Anemia 2.9 3 0.937 0 0 4.8 2.7 0.068 0 1* Neutropenia 1.7 2.2 0.686 1 1* 1.2 2.3 0.064 1 1.1 0.356 Thrombocytopenia 4.3 2.6 0.241 1* 1.2 3.6 3.3 0.781 1 1 ** Gastrointestinal <jats:td colspan="1" rowspan="1

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-01-27
DOI
https://doi.org/10.1200/jco.2025.43.4_suppl.658
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patient-centered adverse event reporting in clinical trials: A novel approach using ECOG-ACRIN E2211.

Laura D. Cramer, Namrata Vijayvergia, Wan Ying Tan, Pamela L. Kunz et al.
Journal of Clinical Oncology
Ethics in Clinical Research
article

Patient-centered adverse event reporting in clinical trials: A novel approach using ECOG-ACRIN E2211.

Laura D. Cramer, Namrata Vijayvergia, Wan Ying Tan, Pamela L. Kunz, Maryam B. Lustberg, Noah Graham, Al B. Benson
article en

Abstract

658 Background: The Common Terminology Criteria for Adverse Events (CTCAE) classifies adverse events (AEs) in clinical trials but traditionally limits the analysis to a single occurrence per patient and grade 3-4 AEs, overlooking frequent and lower grade AEs. We propose a new approach of AE reporting that captures both the safety profile and patient experience. Methods: We analyzed related AEs collected in the ECOG-ACRIN E2211 [Phase II capecitabine + temozolomide (Arm A) vs. temozolomide (Arm B) in advanced pancreatic neuroendocrine neoplasms] by CTCAE v4.0 and limited to hematologic and gastrointestinal (GI) categories for this exploratory analysis. We calculated AE burden, defined as the average occurrence of AE per patient experiencing the AE, measured by total occurrence of AEs, and divided by number of patients who developed the AE. We then compared burden of grade 3-4 AEs vs. grades 1-4 AEs. Sex differences were evaluated using t-tests. Results: For hematologic AEs, 72 patients reported 426 occurrences across grades 1-4 and 24 patients reported 39 occurrences for grades 3-4, resulting in AE burdens of 5.9 (grades 1-4) versus 1.6 (grades 3-4). For GI AEs, 108 patients reported 997 grade 1-4 events, and 13 patients reported 22 grade 3-4 events, resulting in AE burdens of 9.23 versus 1.69, respectively. Sex differences in AE burden are tabulated below (Table). For example, in Arm B, anemia burden was 4.8 (males) vs 2.7 (females) [p=0.068] for grades 1-4 and 0 (males) vs 1 (females) for grades 3 and 4. Conclusions: This AE reporting approach, accounting for the burden across grade 1-4, offers a different and more patient-centered assessment of AEs in clinical trials and may help better identify sex-based differences. Burden of AEs by treatment arm and sex distribution. Burden of Related AEs Categories of AEs Arm A (N=65) Arm B (N=68) Grade 1-Grade 4 Grade 3-Grade 4 Grade 1-Grade 4 Grade 3-Grade 4 Male Female p-value Male Female p-value Male Female p-value Male Female p-value Hematologic Anemia 2.9 3 0.937 0 0 4.8 2.7 0.068 0 1* Neutropenia 1.7 2.2 0.686 1 1* 1.2 2.3 0.064 1 1.1 0.356 Thrombocytopenia 4.3 2.6 0.241 1* 1.2 3.6 3.3 0.781 1 1 ** Gastrointestinal <jats:td colspan="1" rowspan="1

Journal of Clinical OncologyVol. 43(4_suppl)
Northwestern University (US), Fox Chase Cancer Center (US), University of Connecticut (US), Yale Cancer Center (US), Yale University (US), Dana-Farber Cancer Institute (US)
Openalex Percentile: Top 98%
Ethics in Clinical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.